Chemically-modified G-CSF
AssigneeKirin-Amgen, Inc.
InventorsRika Ishikawa, Yuji Okada, Makoto Kakitani
Life of this patent
Estimating the term…
Abstract
The present invention provides a chemically-modified protein prepared by binding polyethylene glycol to a polypeptide characterized by being the product of expression by a host cell of an exogenous DNA sequence and substantially having the following amino acid sequence: ##STR1## The chemically-modified protein according to the present invention has a much longer lasting neutrophil-increasing activity than that of the intact human G-CSF, enabling fewer numbers of administration with a lower dose.
Claims2
A biologically active G-CSF polypeptide having at least one polyethylene glycol molecule covalently attached to at least one amino acid of the polypeptide, wherein said polyethylene glycol molecule is covalently attached through a carboxyl group of an amino acid of the polypeptide.
A biologically active G-CSF polypeptide having at least one polyethylene glycol molecule covalently attached to at least one amino acid of the polypeptide, wherein the amino acid sequence of said G-CSF polypeptide is:
- ##STR7##
Dependencies are inferred from the claim text.